Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF) is currently one of the most potent factors protecting and rescuing neurons in pre-clinical models of Parkinson’s disease. We found a cell-penetrating octapeptide from MANF that protects the cultured dopaminergic neurons from apoptotic death. The small size and cell-penetrating properties makes this peptide an attractive candidate for therapy in Parkinson’s disease as it spreads in the brain better than the larger full-length MANF and gets inside the neurons.
SUNNYVALE, Calif., Nov. 1, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it intends to pursue the identification of one or multiple therapeutic indications for its lead therapeutic candidate MANF that could lead to the therapy receiving orphan drug designation(s) with the Food and Drug Administration (FDA). The strategy is centred on exploiting MANF's unique mechanism of action related to facilitating proper protein folding and processing in the endoplasmic reticulum in order to identify rare and/or ultra-rare diseases where MANF treatment may play a significant role in improving patient outcomes in disease states where no other treatment options are currently available.
SUNNYVALE, Calif., Oct. 25, 2012 -- /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has received positive behavioural efficacy data for MANF in a neurorestoration 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease. The data shows superiority of MANF over GDNF, a neurotrophic factor currently in a Phase 2 clinical trial as a disease-modifying treatment for Parkinson's disease, by demonstrating that when MANF is delivered directly to the primary brain region associated with Parkinson's called the substantia nigra, MANF significantly reduced behavioural deficits in the model, whereas GDNF did not.
SUNNYVALE, Calif., Sept. 26, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease (PD) and Traumatic Brain Injury (TBI) centered around its patented anti-apoptotic therapeutic protein MANF, today announced the publication of positive, peer-reviewed efficacy data for MANF in an animal model of myocardial infarction. The results were published in The Journal of Biological Chemistry (JBC) by the Glembotski Lab at the San Diego State University's (SDSU) Department of Biology and the SDSU Heart Institute. The research paper entitled " Mesencephalic astrocyte-derived neurotrophic factor (MANF) protects the heart from Ischemic damage and is selectively secreted upon ER calcium depletion" reports a ~44% reduction in infarct zone size in MANF-treated mice when compared with controls.
"The generation of positive ischemia/reperfusion in-vivo animal data in a model of myocardial infarction represents a significant scientific milestone for MANF as scientifists look to establish the therapeutic profile of MANF in ischemic heart disease," said Gerald E. Commissiong, President & CEO of Amarantus. "As the research on MANF moves forward around the globe, Amarantus will leverage the data generated by collaborators and independent researchers to improve the value of our IP portfolio as well as overall shareholder value."
Since 2011, the Company has reported positive data in pre-clinical models of Parkinson's disease, Traumatic Brain Injury and Myocardial. The Company owns composition of matter and method of use patents and patent applications for MANF worldwide. Amarantus is focused primarily on the development of a MANF-based treatment for Parkinson's disease.
6. there is more. But this alone, shows significant excitement, and positive reasoning this stock price should do well going forward!
Sentiment: Strong Buy
SUNNYVALE, Calif., Nov. 12, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it has appointed Robert J. Zimmerman, SD as product development advisor. In Dr. Zimmerman's advisory role, he will assist Amarantus management with expansion of the Company's MANF product development strategy. Dr. Zimmerman will also assist in the procurement of relationships with top-tier vendors to ensure that state-of-the art development data are gathered with high quality test article materials. Amarantus expects to gather data in additional indications through its research grant with the Center of Excellence in Apoptosis Research, collaboration with highly-respected academic labs, and through outsourcing efficacy and toxicology studies with independent contract labs.
"I have been involved with Amarantus formally and informally for the past three years supporting the founders as they work tirelessly to advance MANF to a stage where it has real commercial potential," said Robert J. Zimmerman, SD. "While that effort has been centered on Parkinson's disease, I believe additional opportunities exist to diversify this therapeutic candidate. Ischemia/reperfusion, cardiovascular disease, stroke, traumatic brain injury, diabetes and potentially other disease conditions appear to be impacted by MANF based upon preclinical studies and the literature